Last reviewed · How we verify
Erector Spinae Plane Block using 0.2% ropivacaine — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Erector Spinae Plane Block using 0.2% ropivacaine (Erector Spinae Plane Block using 0.2% ropivacaine) — Poznan University of Medical Sciences.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Erector Spinae Plane Block using 0.2% ropivacaine TARGET | Erector Spinae Plane Block using 0.2% ropivacaine | Poznan University of Medical Sciences | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Erector Spinae Plane Block using 0.2% ropivacaine CI watch — RSS
- Erector Spinae Plane Block using 0.2% ropivacaine CI watch — Atom
- Erector Spinae Plane Block using 0.2% ropivacaine CI watch — JSON
- Erector Spinae Plane Block using 0.2% ropivacaine alone — RSS
Cite this brief
Drug Landscape (2026). Erector Spinae Plane Block using 0.2% ropivacaine — Competitive Intelligence Brief. https://druglandscape.com/ci/erector-spinae-plane-block-using-0-2-ropivacaine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab